The Plasticware Paradox

A Blackout, Toilet Paper, and GCC Diagnostics

How the Gulf exports the raw material for molecular medicine, and imports every finished piece of it

The Gulf Cooperation Council (GCC) has invested heavily in genomics, cancer care, and national screening programmes, but the region’s diagnostics manufacturing base remains thin. This essay argues that single-use laboratory plasticware – pipette tips, PCR plates and other consumables – is the weakest link in GCC diagnostics manufacturing and a critical piece of health sovereignty that is still treated as an imported commodity.

On April 28^th 2025, a major electrical failure knocked out power across most of Portugal and Spain. For nearly two days, schools closed, commerce stopped, and most services went dark. It is easy to forget how completely modern life depends on electricity until it is gone.

I made it home with my two daughters (my partner was travelling) and found myself calculating how long the refrigerator and pantry contents would last. Card payments were down too, so I raided their piggy banks and walked to the local supermarket, which was still running on its own solar array.

Some shelves were being stripped, aggressively, but not for the food. Toilet paper.

It was impossible not to think of COVID. In those first weeks of the pandemic, as hospitals filled and supply chains buckled, the item that triggered mass hoarding was toilet paper: something that takes up zero space in daily conversation, zero strategic planning, zero policy attention, until the shelf is empty.

This image of people leaving the supermarkets with trolleys piled 6 feet high with toilet paper, again, stayed with me. I mention it because it describes, very precisely, the relationship that diagnostic laboratories across the Gulf and elsewhere have with a particular object.

This article is about something that sits on every bench in every diagnostic laboratory in the Gulf. You will not find it in any Vision 2030 document, any national health strategy, or any industrial policy framework. It weighs a few grams. It costs less than a dirham or rial. And without it, no PCR test runs, no genome gets sequenced, no clinical chemistry result gets reported.

A pipette tip.

And just as COVID produced its toilet paper crisis, it produced a pipette tip crisis too: less reported, more consequential. Usage more than doubled relative to pre-pandemic baselines within months [1]. Delivery times that had been measured in days stretched into weeks, and in some cases months [1]. Tecan, a Swiss supplier serving hundreds of US laboratories, was forced to draw down emergency reserves while racing to install new production lines [2]. The FDA got involved directly: its acting commissioner stated that the agency had become more engaged in downstream supply chain details than it had ever previously been [3]. Scientists at research institutions were scanning neighbouring labs’ shelves for unused stock [4]. Newborn screening programmes were threatened [4, 5]. A scientist with 21 years of laboratory experience said she had never encountered anything like it [4]. And behind the demand shock, a second failure compounded the first: winter blackouts in Texas forced temporary closure of plants producing polypropylene resin (the raw material for pipette tips), affecting roughly 85 percent of US production capacity in a single event [5]. I was setting up a new lab at the time after receiving the EIC accelerator Grant to develop HepatoPredict, an IVD test to stratify liver cancer patients for transplantation, and living this first-hand. It was nigh impossible to buy laboratory plastics, particularly if related to PCR in any way. Hours on the phone with suppliers, negotiating, cajoling, begging, just to keep working and to meet the tight deadlines we had set ourselves.

Toilet paper and pipette tips: the same psychology, the same structural fragility. One invisible to policy, the other invisible to industrial strategy. That is the problem this article is about. Not the big machines, nor the reagent kits. The plastic.

The global laboratory plasticware market 

Laboratory plasticware (pipette tips, PCR plates, microtubes, Falcon tubes, cryovials, culture flasks) is a global market valued at approximately $2.25 billion in 2024, projected to reach $3 billion by 2030 at a compound annual growth rate of around 4.7% [6]. It is not glamorous. It does not attract much policy attention. But it is the physical substrate of modern molecular medicine. Every COVID PCR test that ran during the pandemic sat in a few grams of injection-moulded polypropylene. Every genome sample processed by the GCC’s national sequencing programmes moves through a sequence of single-use plastic consumables before it becomes data.

Note that these are not commodity items. Diagnostic-grade plasticware must meet biocompatibility standards (ISO 10993 or USP Class VI) and be manufactured in ISO Class 7 or 8 cleanrooms under quality management systems certified to ISO 13485. A 96-well PCR plate must hold dimensional tolerances that allow automation to pipette into the same position, well after well, plate after plate, without error. A filtered pipette tip must prevent aerosol contamination at the orifice to a tolerance of ±0.02 mm. These are precision industrial products that attract significant design and process innovation. They happen to look like disposable plastic.

The global supply is highly concentrated. Thermo Fisher, Corning, Eppendorf, Greiner Bio-One, Sartorius, BRAND. A network of European and North American brand-owners holds the intellectual property, the mould designs, the regulatory approvals, and the distribution infrastructure. Behind them, a growing tier of high-volume Asian manufacturers, particularly in China, runs cleanroom injection-moulding at scale, feeding both OEM supply chains and direct export markets [6].

Eppendorf alone moulds billions of parts per year at its Oldenburg facility, and has expanded production capacity near Shanghai in recent years [7]. That is the shape of this industry: distributed, high-volume, technically demanding, and entirely absent from the Gulf.

What the Gulf actually produces for diagnostics 

And now for the paradox…

The GCC is a major global producer of the polymers that laboratory plasticware is made from. Borouge (the Abu Dhabi-based joint venture between ADNOC and Borealis) produces polyolefins at scale, including medical-grade polypropylene grades explicitly formulated and certified for pharmaceutical and diagnostic applications [8]. SABIC, in Saudi Arabia, markets healthcare polymer grades with full traceability and change-control documentation [9]. These are not generic commodity pellets. They are the same class of material that Eppendorf and Greiner run through their injection-moulding lines to make the tips and plates that GCC laboratories import.

So the Gulf exports medical-grade polypropylene to the world. It then imports back the finished products made from it, at a price that includes European or Chinese manufacturing margin, freight, customs, and regional distributor margin.

The resin leaves through the Strait of Hormuz. It gets moulded into labware in Germany, Austria, or Zhejiang. It returns through the same chokepoint (the same one whose vulnerability became visible to every supply chain manager in the world between 2019 and 2022, and now in 2026 again) and arrives in a GCC laboratory at three to five times the cost of the polymer it started as.

The downstream vacuum in GCC lab consumables 

Survey the GCC-facing lab consumables market and the picture is consistent. The regional distributors (NHS Medical Supplies, Olive Bioscience, REDA Lab, CGenomix, AlGenome) stock JetBiofil, Greiner, Corning, Thermo Fisher, Eppendorf. They operate primarily as importers and resellers. They are good at what they do, I’m certain, but they are not manufacturers at diagnostic scale.

No publicly documented commercial-scale production of diagnostic-grade pipette tips, PCR plates, ELISA plates, or centrifuge tubes exists anywhere in the GCC. Industry analysts describe the UAE laboratory plasticware sector as dominated by established multinationals and local distributors, with domestic manufacturing framed as a future opportunity rather than an existing base [10].

This framing – opportunity rather than base – is important and accurate. And I wonder how come it is not unbearably uncomfortable.

Why GCC diagnostics manufacturing matters now 

The GCC’s diagnostic infrastructure is expanding at a rate that makes this gap structurally significant. The GCC in-vitro diagnostics market was valued at $1.28 billion in 2024 and is projected to reach $1.81 billion by 2033 [11]. Saudi Arabia, the UAE, and Qatar are simultaneously running national genome programmes, building oncology infrastructure, and scaling food safety and pharma QC capacity. Every new sequencer installed, every new PCR laboratory commissioned, every new genome cohort initiated, adds to the volume of imported single-use plastic flowing into the region.

The COVID pandemic provided a stress test that this dependency did not pass. Pipette tip shortages were not a peripheral inconvenience during 2020–2021. They were a real constraint on testing capacity in laboratories worldwide, including in the Gulf [1, 2]. The supply disruption was temporary, but the structural vulnerability that produced it is not.

The operational consequences are real and ongoing: lead-time uncertainty on routine procurement, emergency purchasing at punitive cost, dependence on air freight for items that should move by sea, and exposure to any disruption (logistical, geopolitical, or regulatory) along supply chains that run entirely outside the region.

This is something I struggled with before. When we were developing HepatoPredict, sourcing anxiety was a standing item in our supplier meetings. We demanded documented evidence that every component (every plastic consumable, every reagent) was manufactured in Europe. The reason was never quality preference. It was political: the first Trump administration’s tariff unpredictability made any US-linked supply chain feel like a liability we could not price. By the time I left that company, we were designing the next product, the concern had only deepened as tariffs and blockades changed on a weekly basis. The question was no longer whether to source in Europe; it was whether European supply chains themselves could be considered stable, given the trajectory of US trade policy and the retaliatory measures it was provoking.

These were not abstract conversations. They were procurement decisions, made under genuine uncertainty, about items that cost fractions of a euro each. A single-use plastic tube. A filtered pipette tip. The kind of object that takes zero minutes of daily thought, until it is unavailable, or unaffordable, or delayed six weeks because a polymer plant in Texas lost power in a winter storm. Note that if you are a manufacturer of In Vitro Diagnostics, or operating a Laboratory Developed Test, you build a technical file that specifies every component in your assay. When it changes, the technical dossier needs to be updated and, in many jurisdictions, revalidated. If you happen to be using uber special low-stick tubes to prevent loss of the nucleic acids in your assay that were a pain to source and that required months optimisation, finding another one functionally equivalent is the stuff of nightmares.

The industrial argument for Gulf diagnostic plasticware 

In our increasingly conflictual world it is easy to conclude that I’m defending some ‘let’s do everything ourselves’ agenda. I am not. I don’t defend that the Gulf should build a vertically integrated labware conglomerate to compete with Thermo Fisher. That is not the argument.

The argument is that laboratory plasticware sits at the accessible end of the diagnostic manufacturing value chain. It requires precision, not complexity. The knowledge is industrially standardised: injection-moulding machine manufacturers sell turnkey medical labware cells; the process parameters for tips and PCR plates are documented; the quality systems are certifiable. What is required is capital allocation, regulatory clarity, and the decision to treat single-use diagnostic consumables as a manufactured good rather than a purchased commodity.

The realistic model here is not greenfield construction but market-leverage manufacturing. Eppendorf did not build its Shanghai facility to pioneer new technology. It built it because the Chinese market had grown large enough to make localising supply commercially rational [7]. The GCC market is approaching that threshold, and unlike China, it sits on the polymer feedstock. The negotiating position for a Gulf-based joint venture with a Tier 1 European or Asian manufacturer is stronger than the current framing suggests. The asset is not just market size. It is vertical adjacency: medical-grade polypropylene produced locally, fed directly into a cleanroom moulding operation, serving a growing captive market with sovereign distribution infrastructure behind it. That is not a speculative proposition. It is an industrial logic waiting to be applied.

That decision has not been made: not in any Vision document, not in any NIDLP annex, not in any Gulf industrial strategy I have reviewed. The IVD column in GCC diversification frameworks is effectively blank. I believe this is because the framing has been wrong: diagnostics has been treated as a health service delivery question, not an industrial one.

This is not a gap. This is a specification for an investment.

A conversation GCC decision-makers are not having 

In Qatar, at HealthTech, we are building a new platform with a strong molecular diagnostics innovation component. The plasticware gap described above is not a theoretical concern for us; it is a design parameter and a procurement reality.

What I notice, working across European diagnostics science and Gulf health infrastructure, is that the industrial argument for regional manufacturing of diagnostic consumables is well understood at the bench level (by the scientists and laboratory managers who live with the procurement reality) and almost entirely absent at the policy and investment level, where the decisions that would actually change it are made.

The Gulf is at an unusual industrial moment. Abundant polymer feedstock, expanding diagnostics markets, sovereign capital looking for manufacturing anchors, and post-COVID supply chain awareness that has not yet translated into strategic action. That window will not stay open indefinitely.

If you are thinking about this class of problem, from industrial policy, sovereign investment, health infrastructure, or diagnostics manufacturing, I would be glad to hear your perspective. The conversation this industrial moment requires is not one person’s to have.

Sources

[1] Becker’s Hospital Review. Pandemic spurring hospital shortage of pipette tips, sterile water, analysis finds. February 2021. https://www.beckershospitalreview.com/supply-chain/pandemic-spurring-hospital-shortage-of-pipette-tips-sterile-water-analysis-finds/

[2] Becker’s Hospital Review. Shortage of pipette tips is slowing US COVID-19 testing. 2020. https://beckershospitalreview.com/supply-chain/shortage-of-pipette-tips-is-slowing-us-covid-19-testing-2.html

[3] Bloomberg Law. Pipette Tip Supply Gaps Snarl Cash Infusion for Covid-19 Testing. March 2021. https://news.bloomberglaw.com/health-law-and-business/pipette-tip-supply-gaps-snarl-cash-infusion-for-covid-19-testing

[4] STAT News. How blackouts, fires, and a pandemic are driving shortages of pipette tips and hobbling science. April 2021. https://www.statnews.com/2021/04/28/pipette-tips-shortage/

[5] ASH Clinical News / American Society of Hematology. Pipette Tip Shortage Hinders Scientific Work Worldwide.December 2021. https://ashpublications.org/ashclinicalnews/news/5638/Pipette-Tip-Shortage-Hinders-Scientific-Work

[6] Grand View Research. Laboratory Plasticware Market Size, Share & Growth Report 2030. 2024. https://www.grandviewresearch.com/industry-analysis/laboratory-plasticware-market-report

[7] Eppendorf AG. Eppendorf expands manufacturing footprint in China. Corporate communications / annual reports. https://www.eppendorf.com

[8] Borouge / Borealis. Bormed healthcare polyolefins for medical and diagnostic devices. Product documentation. https://www.borouge.com

[9] SABIC. Healthcare polymer grades and traceability documentation. Product documentation. https://www.sabic.com

[10] GM Insights. Laboratory Plasticware Market Size and Share Analysis. 2024. https://www.gminsights.com/industry-analysis/laboratory-plasticware-market

[11] IMARC Group. GCC In-Vitro Diagnostic Devices Market Report 2025–2033. 2024. https://www.imarcgroup.com/gcc-in-vitro-diagnostic-devices-market